Compositions containing γ-aminobutyric acid

By providing compositions containing GABA, the shortcomings of existing technologies in improving or preventing states of confusion and bewilderment are overcome, especially in cognitive load scenarios, achieving the effects of improving cognitive efficiency and reducing psychological load, and applicable to beverages, foods and supplements.

CN123124885APending Publication Date: 2026-11-17PHARMA FOODS INT CO LTD +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202580021360.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-03-15
Filing Date
2025-03-14
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In the prior art, the effects of γ-aminobutyric acid (GABA) in improving or preventing states of confusion and/or bewilderment have not been fully utilized, especially in states caused by cognitive overload, where there is a lack of effective compositional solutions.

Method used

A composition containing γ-aminobutyric acid (GABA) as an active ingredient is provided for improving or preventing states of confusion and/or bewilderment. It is evaluated by POMS2 and is suitable for use in beverages, foods, supplements, etc., especially for reducing confusion and bewilderment caused by cognitive load, and is suitable for scenarios such as e-sports.

Benefits of technology

By ingesting a combination containing GABA, it is possible to significantly improve or prevent states of confusion and bewilderment caused by cognitive load, enhance the subject's calm judgment and productivity, reduce stress and psychological load, and improve task processing efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123124885A_ABST
    Figure CN123124885A_ABST
Patent Text Reader

Abstract

According to the present invention, a composition for improving or preventing a state of confusion and / or bewilderment in a subject is provided, the composition containing γ-aminobutyric acid (GABA) as an active ingredient. Preferably, the composition of the present invention is capable of improving or preventing states of confusion and / or bewilderment as assessed by the POMS2 (Profile of Mood States 2nd Edition).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a composition containing γ-aminobutyric acid (GABA), and more particularly to a GABA-containing composition for improving or preventing a state of confusion and / or bewilderment in an object. Background Technology

[0002] As an amino acid widely distributed in nature and whose flavor is not impaired even when added to food, gamma-aminobutyric acid (GABA, 4-aminobutyric acid) has attracted attention in recent years. GABA is known to be an inhibitory neurotransmitter abundant in the central nervous system of mammals. It exerts a relaxing effect and anti-stress effect by inhibiting the excessive secretion of excitatory neurotransmitters, thereby calming nerve excitation. Furthermore, GABA is known to have various physiological activities, including lowering blood pressure, reducing cholesterol, and inhibiting immune system decline. Because GABA is also found in vegetables, grains, and the human body, it is easily added to food, and chocolates and many supplements containing GABA are currently on the market. Summary of the Invention

[0003] means of solving technical problems The inventors have discovered that GABA can improve or prevent the state of confusion and / or bewilderment of objects.

[0004] Therefore, based on the main points of the present invention, the following invention is provided.

[0005] (Project 1) A composition for improving or preventing a state of confusion and / or bewilderment in an object, wherein the composition contains γ-aminobutyric acid (GABA) as an active ingredient.

[0006] (Project 2) According to the composition described in the above-mentioned project, the aforementioned state of confusion and / or bewilderment is evaluated using POMS2 (Profile of Mood States 2nd Edition).

[0007] (Project 3) The composition according to any of the above items, wherein the composition inhibits and / or prevents the rise in the evaluation value of the above-mentioned confusion and / or bewilderment state.

[0008] (Project 4) The composition according to any of the above items is used to improve or prevent states of confusion and / or bewilderment caused by cognitive load.

[0009] (Project 5) A composition for improving or preventing states of confusion and / or bewilderment caused by cognitive load on an object, the composition containing γ-aminobutyric acid (GABA) as an active ingredient, the states of confusion and / or bewilderment being evaluated using POMS2 (Profile of Mood States 2nd Edition).

[0010] (Project 6) The composition according to any of the above items, wherein the cognitive load is caused by e-sports.

[0011] (Project 7) The composition according to any of the above items, wherein the content of the above-mentioned GABA is about 10 mg to about 1000 mg.

[0012] (Project 8) The composition according to any of the above items, wherein the content of the above-mentioned GABA is at least 200 mg.

[0013] (Project 9) The composition according to any of the above items, wherein the composition is ingested orally.

[0014] (Project 10) The composition according to any of the above items, wherein the composition is a beverage, food, supplement, food additive, quasi-medicine or pharmaceutical.

[0015] (Project 11) The composition according to any of the above items, wherein the composition is in the form of a liquid, powder, tablet or capsule.

[0016] (Project 12) The composition according to any of the above items, wherein the composition is used to improve scores in games and / or e-sports.

[0017] (Project 13) The composition according to any of the above items, wherein the composition is a food product, and the packaging of the food product is affixed with a label indicating that it contains GABA as an active ingredient and improves or prevents confusion and / or disorientation.

[0018] (Project 14) The composition according to any of the above items is used to improve or prevent a state of mental dullness and / or decreased attention.

[0019] (Project 15) A method for improving a confused and / or disoriented state of an object, comprising the step of administering a composition containing γ-aminobutyric acid (GABA) as an active ingredient to the object.

[0020] In this application, it is intended that, in addition to the explicitly stated combinations, one or more of the features described above may be further combined and provided. Furthermore, those skilled in the art will recognize other embodiments and advantages of this application upon reading and understanding the following detailed description.

[0021] Furthermore, those skilled in the art can clearly understand the features and significant effects of this application other than those described above by referring to the following embodiments and accompanying drawings.

[0022] Invention Effects According to the present invention, by ingesting a composition containing GABA, it is possible to improve or prevent a person's state of confusion and / or bewilderment. Therefore, the person is able to make the same calm and rational judgments as usual, and decision-making based on appropriate information is facilitated, thus having high utility value in daily life.

[0023] Furthermore, by utilizing the compositions of the present invention to alleviate states of confusion and / or bewilderment, it is possible to improve productivity and operational efficiency in objects, enhance task quality, and reduce stress and psychological burden. Attached Figure Description

[0024] Figure 1 This is a graph showing the impact of sample intake on POMS2 results in a game (multitasking) experiment, comparing the GABA intake group and the placebo intake group.

[0025] Figure 2 It is a chart showing the game (multitasking) scores of the GABA intake group and the placebo intake group.

[0026] Figure 3 This is a graph showing the impact of sample intake on POMS2 results in a game (single-task) experiment, comparing the GABA intake group and the placebo intake group.

[0027] Figure 4A This is a chart comparing the game (single task) scores of the GABA intake group and the placebo intake group. It displays the average of the total score (total score) and the Acc Total score (overall accuracy (%)).

[0028] Figure 4BThis is a chart comparing the game (single task) scores of the GABA intake group and the placebo intake group. It displays the average of the total reaction speed score (overall reaction speed (%)) and the total kill score (number of kills).

[0029] Figure 5 This is a graph showing the effect of sample intake on the CB score of POMS2 in a game (multi-task) exercise, in the presence of theanine, ornithine hydrochloride, or saffron extract. Detailed Implementation

[0030] The present application will now be described with reference to the best mode. It should be understood that throughout this specification, unless otherwise specified, the singular form includes the concept of its plural form. Therefore, it should be understood that articles in the singular form (e.g., "a," "an," "the," etc. in English), unless otherwise specified, also include the concept of their plural forms. Furthermore, it should be understood that the terms used in this specification, unless otherwise specified, are used in the sense commonly understood in the art. Therefore, unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains. In case of conflict, this specification (including definitions) shall prevail.

[0031] The following provides appropriate definitions of terms and / or basic technical content used in this specification.

[0032] In this specification, “about” means ±10% of the value that follows.

[0033] In this specification, "confusion and / or bewilderment" refers to the "Confusion-Bewilderment (CB)" in the POMS2 (Profile of Mood States 2nd Edition) psychological test, or the evaluation in other psychological tests known in the field that are equivalent to POMS2 CB, which, due to any factor, temporarily and significantly increases or rises in the subjects after the occurrence of that factor compared to before the occurrence of that factor. Examples of other psychological tests known in the field that are equivalent to POMS2 CB include "instability" in the "Self-Assessment Symptom Survey (edited by the Japanese Society for Industrial Hygiene Fatigue Research (2000))" and "depression" in the "Simplified Occupational Stress Questionnaire."

[0034] In this specification, when an ingredient “improves or prevents” a state of confusion and / or bewilderment, it means that the degree of confusion and / or bewilderment is significantly reduced when the ingredient is ingested, compared to the degree of confusion and / or bewilderment when the ingredient is not ingested.

[0035] In this specification, "temporarily" after the occurrence of a factor means within 3 hours from the occurrence of the factor.

[0036] In this manual, "e-Sports" is short for "electronic sports," which broadly refers to competitions conducted using electronic devices. In a narrower sense, "e-sports" refers to competitive sports when computer games or video games are considered sports. E-sports competitions include not only sports games but also shooting games, simulation games, fighting games, racing games, puzzle games, card games, and role-playing games, but are not limited to these.

[0037] In this manual, "VDT operation" refers to an operation performed using a VDT (Visual Display Terminal) such as a monitor and keyboard.

[0038] In this manual, "digital work" primarily refers to tasks that effectively utilize computers and the internet. Specific examples of digital work include: communication using tools such as email and chat, data processing, database management, website and application development, online marketing, and digital content creation.

[0039] (Preferred Implementation) The preferred embodiments of this application are described below. The embodiments provided below are for a better understanding of this application, and the scope of this application should not be limited to the following description. Therefore, it is apparent that those skilled in the art can make appropriate modifications within the scope of this application by referring to the description herein. Furthermore, the following embodiments of this application can be used individually or in combination.

[0040] In one aspect of the invention, a composition for improving or preventing a state of confusion and / or bewilderment in an object is provided, the composition containing γ-aminobutyric acid (GABA) as an active ingredient. In one embodiment, a composition for improving or preventing a state of confusion and / or bewilderment in an object is provided, the composition containing γ-aminobutyric acid (GABA) as an active ingredient for improving or preventing a state of confusion and / or bewilderment in an object.

[0041] Since γ-aminobutyric acid (GABA) is an amino acid widely distributed in nature, such as vegetables and grains, in one embodiment of the present invention, there are no particular limitations on its source, as long as GABA is a substance that can be used in beverages and foods. For example, extracts or purified products of plants containing GABA can be used, or it can be prepared from fermentation products obtained by adding glutamate decarboxylase or microorganisms such as lactic acid bacteria containing glutamate to raw materials containing glutamate. Regarding GABA-containing products and commercially available GABA, it can also be used in the compositions of the present invention as long as it does not impair the effects brought about by the compositions of the present invention.

[0042] In one embodiment, the composition of the present invention, by ingesting by a subject, can improve or prevent the subject's state of confusion and / or bewilderment. The state of confusion and / or bewilderment can be evaluated using POMS2 (Profile of Mood States 2nd Edition) or other equivalent psychological tests known in the art. Other psychological tests known in the art include, but are not limited to, POMS (Profile of Mood States), STAI (State-Trait Anxiety Inventory), DAMS (Depression and Anxiety Mood Scale), and PMS (Positive Mood Scale). Among these, the "focus mood" in PMS can be listed as an example of a CB equivalent to POMS2. Psychological tests, such as those for adults and adolescents, have different testing methods depending on the target population, and there are also simplified versions of tests, such as full-item versions or abbreviated versions, which differ depending on the number of questions asked. The testing method and the number of questions can be appropriately selected according to the subject's condition. Therefore, in one embodiment of this application, a composition is provided for improving or preventing confusion and / or bewilderment in an object evaluated by POMS2, the composition containing γ-aminobutyric acid (GABA) as an active ingredient.

[0043] For example, in POMS, factors of "Anger-Hostility (AH)," "Confusion (C)," "Depression-Dejection (D)," "Fatigue (F)," "Tension-Anxiety (TA)," "Vigor (V)," and "Total Mood Disturbance (TMD)" are measured.

[0044] POMS2 is a questionnaire used for subjective evaluation. In POMS2, factors are measured for “Anger-Hostility (AH),” “Confusion-Bewilderment (CB),” “Depression-Dejection (DD),” “Fatigue-Inertia (FI),” “Tension-Anxiety (TA),” “Vigor-Activity (VA),” “Friendliness (F),” and “Total Mood Disturbance (TMD),” and mood states are evaluated over a specified time period. The “Confusion-Bewilderment” score is composed of sub-items such as “confused mind, disoriented, unstable, lack of confidence, and inability to concentrate.”

[0045] In STAI, factors of "state anxiety (constantly changing anxiety states)" and "trait anxiety (a personality tendency to become anxious)" are measured.

[0046] In DAMS, factors of "affirmative mood", "depressive mood" and "anxious mood" are measured.

[0047] In PMS, factors of "relaxed mood", "affinity mood", "pleasant mood" and "focused mood" are measured.

[0048] Examples of POMS2 include "POMS2 Adult Full Edition (Profile of Mood States 2nd Edition - Adult; POMS2-A)" and "POMS2 Adult Short Edition (Profile of Mood States 2nd Edition - Adult Short; POMS2-A Short Version)" (Heuchert, JP et al., Japanese version: translated by Kazuhito Yokoyama, Kaneko Shobo, 2015). Regardless of whether the full version or the short version is used, the confusion and / or bewilderment inherent in this invention can be assessed.

[0049] The POMS2 Adult Full Version and POMS2 Adult Short Version Mood Status Scale is a test that objectively measures mood at the time of the survey using a questionnaire. It is used internationally in various fields such as medicine, workplace, education, and sports guidance to measure the treatment process of mental disorders (depression, anxiety disorders, etc.), screening of mental health groups in hospitals and workplaces, and measuring the effects of exercise and relaxation.

[0050] In the "POMS2 Adult Full Item Version," participants answer questions consisting of 65 items, while in the "POMS2 Adult Short Version," participants answer questions consisting of 35 items, and these answers are used to represent scores on the aforementioned factors (or scales). The "Confusion / Disorder" factor in POMS2 reflects low cognitive efficiency and anxiety levels in participants. Specifically, it can be assessed through items such as slowed thinking, decreased attention, mental confusion, disorientation, instability, lack of confidence, inability to concentrate, unclear thinking, forgetfulness, uncertainty, and inability to think systematically. The definitions of other factors are as described in the POMS2 manual and other relevant documents.

[0051] Regarding the effects of GABA intake, there are several reports that have conducted subjective evaluations in POMS / POMS2 (e.g., references 1-4 in Table 1 below).

[0052] Table 1

[0053] These studies reported trials involving ingestion of 25–100 mg of GABA, which showed significant improvements in POMS / POMS2 scores for fatigue (F) and energy / vitality (V) compared to placebo. However, no improvements were reported in scores for confusion and / or disorientation (CB). Furthermore, *Applied Pharmacology* 72(3 / 4) 51–56 (2007) reported no change in POMS confusion and / or disorientation (CB) even after ingesting 180 g of soy milk with a high natural GABA content (30 mg of GABA) (Figure 4).

[0054] On the other hand, evaluations related to concentration and relaxation based on GABA intake include Japanese Patent Application Publication Nos. 2005-013127, 2006-061088, and 2005-348656. In Japanese Patent Application No. 2005-013127, concentration was evaluated by administering GABA-infused chocolate and performing input and calculation tests on a word processor, but subjective evaluations using the POMS / POMS2 method were not conducted. In Japanese Patent Application No. 2006-061088, concentration was evaluated by administering GABA and performing golf tee shot and calculation tests, but subjective evaluations using the POMS / POMS2 method were not conducted. In Japanese Patent Application No. 2005-348656, the relaxation effect of GABA was measured, and brain waves and chromogranin A in saliva were used as indicators of relaxation. The STAI (State-Trait Anxiety Scale) was used as a subjective evaluation, but subjective evaluations using the POMS / POMS2 method were not conducted. In addition, regarding "GABA inhibits stress in men and women with acrophobia on suspension bridges," URL: https: / / web.archive.org / web / 20230921144250 / http: / / www.gabastress.jp / effect / 04-2 While the text states that GABA intake resulted in a reduction of confusion, depression, tension, and anxiety compared to when no intake was taken, it does not mention that GABA intake can improve or prevent states of confusion and / or bewilderment.

[0055] In addition, L-theanine and hop extract are known to have relaxing effects. Among these, while there are no reports of significant improvement in POMS / POMS2 CB scores with L-theanine and hop extract, they are known to show a tendency to improve these scores.

[0056] Specifically, regarding L-theanine, a functional food application (application number I603) disclosing that consuming 200 mg of theanine resulted in a decrease in the CB (concentration ratio) score was reported. Furthermore, Figure 4 of the literature used in this application (J Physiol Anthropol 31, 28 (2012)) shows no significant difference in the change in CB(C) score, indicating a minor change. Additionally, Figure 6 of Japanese Patent Application Publication No. 2019-520806 shows that green tea extract containing theanine, proanthocyanidins, and catechins improved the CB score of POMS. Moreover, Table 3 of Japanese Patent Application Publication No. 2007-31309 shows that while all scores of POMS2, including the CB score, were improved by combining tryptophan, L-theanine, and GABA, no improvement in the CB(C) score was observed in combinations of two of these three ingredients.

[0057] Regarding hop extract, Table 5 of the international publication WO2019 / 181058 reports a tendency to improve CB fraction of POMS2 through ingestion of hop oxidation reactants.

[0058] As mentioned above, the effect of GABA intake on improving the POMS2 CB (Confusion-Breakpoint) score, the effect of GABA intake on improving concentration in simple tasks, the relaxation effect, and the inhibitory effect of GABA intake on confusion, depression, and anxiety caused by high-altitude stress, can be said to be effects exerted in the organism through different mechanisms. Although not bound by theory, while suspension bridges (high-altitude stress) and MPG (Mobalytics Proving Ground) games (parallel processing tasks) share the commonality of inducing stress in organisms, they differ in their specific details, exhibiting different characteristics such as situation-dependent stress (high-altitude stress) and cognitive load stress (parallel processing tasks). Specifically, the confusion, depression, and anxiety caused by suspension bridges (high-altitude stress) are mainly emotional responses to environmental stressors (height, fear stimuli). In such responses, physiological stress responses, including those of the amygdala and sympathetic nervous system, play a major role in their inhibition (Journal of Psychiatry (2010), Vol. 112, No. 8, pp. 797-805). On the other hand, stress associated with parallel tasks involving multiple operations simultaneously is a cognitively loaded stress, as assessed by POMS2 CB scores. In coping with such stress, efficient allocation of working memory and attentional resources centered on the prefrontal cortex is important, thereby improving cognitive performance and task processing ability, reflected in improved CB scores.

[0059] Furthermore, the criteria for eliminating this success differ between stress associated with simple tasks, high-altitude stress, and stress associated with parallel tasks (parallel processing). In the former, the goal is to overcome emotional stability such as fear and tension, while in the latter, the benchmark is measurable cognitive outcomes such as task accuracy and efficiency. This distinction is considered to confirm that the two are validated through different mechanisms. Therefore, the stress responses associated with simple tasks, high-altitude stress, and parallel tasks (parallel processing) can be seen as originating from different aspects of emotion and cognition, and can be said to be caused by different mechanisms. Thus, the effects of GABA intake on improving concentration and relaxation in simple tasks, and the inhibitory effects of GABA intake on confusion, depression, and anxiety caused by high-altitude stress, etc., and the effect of GABA intake on improving the POMS2 CB score of subjects, can be seen as corresponding to differences in the stress-generating mechanisms, with effects exerted in the organism by different mechanisms.

[0060] In one embodiment of this application, the GABA-containing composition of this application is capable of inhibiting and / or preventing an increase in the confusion and / or bewilderment state, or an increase in the evaluation value of the confusion and / or bewilderment state. As mentioned above, the effect of GABA intake on the confusion and / or bewilderment state (CB) has been unknown until now, but in this invention, as shown in the examples, it has been found that by ingesting a GABA-containing composition, an increase in the CB (confusion-bewilderment) score of POMS2 can be inhibited or improved. Therefore, in one embodiment of this application, a composition is provided for inhibiting and / or preventing an increase in the confusion and / or bewilderment state, or an increase in the evaluation value of the confusion and / or bewilderment state, wherein the composition contains γ-aminobutyric acid (GABA) as an active ingredient.

[0061] In one embodiment of this application, a state of confusion and / or bewilderment can be caused by cognitive load on an object. Cognitive load refers to the total amount of mental activity exerted on working memory and attentional resources at any given time; for example, it means the mental effort or requirement necessary for an object to understand or learn certain information or to complete a certain task, and it is distinct from emotional reactions. Furthermore, cognitive load depends on the limitations of the object's working memory and attentional resources, as well as the object's ability to process new information. Examples of cognitive load include, for example, long hours of labor, intellectual labor, e-sports, VDT work, digital work, games (video games, computer games, and mobile games, etc.), and it is a mental activity exerted on working memory and attentional resources due to multiple factors, but is not particularly limited.

[0062] In one embodiment of this application, the state of confusion and / or bewilderment can be caused by a single task or by multiple tasks. In one embodiment, multiple tasks include an object simultaneously performing multiple jobs, actions, topics, and / or tasks. For example, in the case of VDT jobs, the following jobs, actions, etc., can be listed as single tasks and multiple tasks, respectively.

[0063] <Single Task> • Typing games (simple repetitive data input) • Shooting computer games that only involve shooting targets (using only the left mouse button with one hand. Excluding games where you use the keyboard to switch weapons, change view, move forward, backward, left, right, jump, crouch, or reload). Multitasking • Shooting games: While shooting, players can simultaneously switch weapons, reload, move forward, backward, left, and right, switch viewpoints, and check the map. Racing games: Simultaneously control the accelerator, brake, and left / right steering. In addition, in other embodiments, in the case of tasks other than VDT ​​operations, the following operations, actions, etc. can be listed as single tasks and multiple tasks, respectively.

[0064] <Single Task> Kraepelin test (repeated simple addition), etc. Multitasking • Car driving: operating the steering wheel, turn signals, etc., foot controls, observing other vehicles, signals, and making judgments based on human behavior, etc. • Piano performance: different movements of the left and right hands, footwork, etc. Esports refers to sports that use computer games and video games (PC (Personal Computer), home consoles, mobile applications, VR, etc., games not limited by the device used) as competition events. Esports also includes, for example, sports that gamify actual sports or newly created virtual sports and are controlled by human players (in the case of competitive matches, the opponent can be a computer-simulated opponent). Furthermore, virtual sports refer to sports that simulate real-world sports or newly created virtual sports through computer simulation, conducted under certain rules and algorithms. Virtual sports consist of virtual players (data mimicking real-world athletes) and user-generated virtual players (data based on specific rules), competing through computer simulation.

[0065] In one implementation, the type of game in esports is not particularly limited and can be any type of game. For example, it can be fighting games, sports games, shooting games, racing games, puzzle games, word games, card games, board games, role-playing games, or simulation games. Furthermore, esports can be individual or team competitions. Additionally, it can be a sport where humans compete against each other as players, or a sport where humans compete against computers (e.g., AI or robots).

[0066] VDT (Visual Display Terminal) work refers to work performed using a monitor, keyboard, and other VDTs. Furthermore, digital work primarily refers to work that effectively utilizes computers and the internet. Because VDT and digital work involve prolonged screen time, they can sometimes lead to eye fatigue and stress. The composition of this invention can improve or prevent states of confusion and / or bewilderment caused by fatigue and / or stress.

[0067] In one embodiment, the game includes games played using any electronic device such as TV games, computer games, and mobile games. The game type is not particularly limited; for example, it can be a fighting game, sports game, shooting game, racing game, puzzle game, word game, card game, board game, role-playing game, or simulation game. The composition of the present invention can improve or prevent the confusion and / or bewilderment experienced by the subject while engaging in e-sports, thereby enabling higher scores or more efficient progress in the game.

[0068] In one embodiment, the composition of the present invention is ingested by the subject before performing the task, and may be ingested to obtain the effects of the composition of the present invention. The composition of the present invention may be ingested at least 5 hours before the subject performs the task, up to about 1 minute before, or just before the subject performs the task. As an upper limit (maximum time) for the ingestion timing, it may be ingested at least about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, or about 7 hours before the subject performs the task. As a lower limit (minimum time) for the ingestion timing, it may be ingested at least about 50 minutes, about 45 minutes, about 40 minutes, about 35 minutes, about 30 minutes, about 25 minutes, about 20 minutes, about 15 minutes, about 10 minutes, about 5 minutes, about 4 minutes, about 3 minutes, about 2 minutes, about 1 minute before, or just before the subject performs the task. The ingestion timing can be any range between these lower and upper limits. By ingesting the composition of the present invention before undertaking a task, it is possible to improve or prevent confusion and / or bewilderment experienced by the subject during the task. In one embodiment, the timeframe for ingesting the composition of the present invention before undertaking a task can be appropriately set according to the type, content, or difficulty of the task, the state or nature of the subject, or the degree of confusion and / or bewilderment.

[0069] In one embodiment of the present invention, the content of GABA in the composition of the present invention is not particularly limited, depending on the method of administration, etc., as long as it is a concentration or weight sufficient to achieve the effect of the composition of the present invention. The content of GABA in the composition of the present invention is preferably from about 10 to about 1000 mg. As a lower limit, it can be, for example, more than about 10 mg, more than about 30 mg, more than about 50 mg, more than about 70 mg, more than about 100 mg, more than about 150 mg, more than about 200 mg, more than about 300 mg, more than about 400 mg, more than about 500 mg, or more than about 700 mg. As an upper limit, it can be, for example, less than about 1000 mg, less than about 800 mg, less than about 700 mg, less than about 600 mg, less than about 500 mg, less than about 400 mg, less than about 300 mg, less than about 200 mg, or less than about 100 mg. The content can be any range between these lower and upper limits.

[0070] In one embodiment of the present invention, the composition of the present invention may contain any additives other than GABA, and any ingredients that can be used in a composition that can be ingested. Examples of such additives and ingredients include vitamins such as vitamin E and vitamin C, minerals, nutrients, physiologically active ingredients such as flavorings, excipients, binders, emulsifiers, isotensinants, buffers, solubilizers, preservatives, stabilizers, antioxidants, colorants, coagulants, or coating agents, but are not limited to these.

[0071] In one embodiment of the present invention, the composition of the present invention is not particularly limited in form as long as it contains GABA. For example, it can also be used as a pharmaceutical composition, beverage and food (including functional foods such as foods for specific health purposes, nutritional functional foods, and functionally labeled foods, health supplements, health foods, etc.), food additive, quasi-pharmaceutical, or pharmaceutical. As a functional label, for example, labels such as "Contains GABA as an active ingredient to prevent, alleviate, or improve states of confusion or bewilderment" or "Improves or prevents states of sluggish thinking and / or decreased attention" can be used, and it can be provided as packaged food with such labels.

[0072] In one embodiment of the present invention, the composition of the present invention can be taken orally. When used as an oral dosage form, it can be in various forms, such as tablets (including coated tablets), capsules, powders, granules, powders, liquids, suspensions, emulsions, granules, powders, pills, pastes, creams, caplets, gels, chewable tablets, sticks, etc. Furthermore, after being adjusted to a form that is easy to mix, such as powder or granules, it can also be used as a raw material for other pharmaceuticals.

[0073] In one embodiment of the present invention, the composition of the present invention can be used for non-therapeutic purposes. Ingesting the composition of the present invention into a subject can also serve as a non-therapeutic method for improving or preventing a subject's state of confusion and / or bewilderment. Such a method does not involve therapeutic or medical procedures, and the subject is not particularly limited, but is preferably a healthy person. By ingesting the composition of this application into such a healthy person, a state of confusion and / or bewilderment can be improved or prevented. Furthermore, when used as a medicine or quasi-medicine, the effects of improving or preventing a state of confusion and / or bewilderment can also be claimed.

[0074] The compositions of the present invention can be used for therapeutic purposes; therefore, in other aspects of the invention, a method for improving a subject’s confused and / or disoriented state is provided, the method comprising the step of administering a composition containing γ-aminobutyric acid (GABA) as an active ingredient to the subject.

[0075] In one embodiment of the present invention, the daily or per-use intake of GABA contained in the composition of the present invention can be appropriately set according to the form of the composition, the method of intake, the purpose of use, and the age, weight, symptoms, etc. of the person taking the GABA. For example, from the viewpoint of making the effect of GABA contained in the composition of the present invention more significant, it is preferable to take the GABA contained in the composition of the present invention at a daily intake of about 10 mg / day or more, and more preferably at a daily intake of about 25 mg / day or more, about 50 mg / day or more, about 60 mg / day or more, about 80 mg / day or more, about 100 mg / day or more, about 120 mg / day or more, about 150 mg / day or more, about 180 mg / day or more, about 200 mg / day or more, about 300 mg / day or more, about 400 mg / day or more, about 500 mg / day or more, about 800 mg / day or more, or about 1000 mg / day or more. There is no particular limitation on the upper limit of daily intake of GABA contained in the compositions of the present invention, as long as it is within the range that can exert the effect of improving or preventing the state of confusion and / or bewilderment brought about by the compositions of the present invention.

[0076] In one embodiment of the present invention, the frequency of application of the method of the present invention, or the frequency of intake of the composition of the present invention, may be taken once a day or in multiple portions within the desired intake range. Furthermore, the intake period may be appropriately set within the range that can achieve the improvement or prevention effect of the confusion and / or bewilderment caused by the composition of the present invention.

[0077] In one embodiment, by ingesting the composition of the present invention, a state of confusion and / or bewilderment in the subject can be improved or prevented, thereby enabling higher scores or more efficient progress when working on a task.

[0078] In other embodiments, the compositions of the present invention can be provided as compositions for suppressing and / or preventing an increase in the confusion and / or bewilderment state of an object, or an increase in the evaluation value of a confusion and / or bewilderment state. By ingesting the compositions of the present invention, scores can be improved or efficient progress can be achieved when dealing with a task.

[0079] In this specification, "or" is used when "at least one or more" of the items listed in the text can be used. "Or" is used in the same way. In cases where it is explicitly stated in this specification as a "range" of "two values," that range also includes the two values ​​themselves.

[0080] All scientific literature, patents, patent applications, and other references cited in this specification are cited here as a whole to the extent that they are identical to their respective specific descriptions.

[0081] For ease of understanding, preferred embodiments have been shown to illustrate this application. The following description is based on embodiments; however, the above description and the following embodiments are provided for illustrative purposes only and are not intended to limit the scope of this application. Therefore, the scope of this application is not limited to the specific embodiments and examples described in this specification, but is defined only by the claims.

[0082] Example (Example 1: Experimental Design A (Multi-task)) The study evaluated whether GABA intake improved POMS2 scores under a multi-task approach. The experimental design is shown below. For brainwave measurements, the analysis algorithm of the brainwave analysis application (Sports Sensibility, KANSEI) provided by Little Software was used.

[0083] <Design of Experiments A (Multi-Task)> • Participants: 9 (1 excluded, 8 for analysis) • Instrument used: Simple EEG meter • Sample: GABA (200mg) or placebo (dextrin) + 30ml water • Measurement items: brainwaves, simplified POMS2, MPG (game-related) score • Double-blind crossover trial (washout period: 1 week) MPG (Mobalytics Proving Ground) is a game that measures the basic skills of esports players. https: / / pg.mobalytics.gg / The game involves three tasks simultaneously: shooting targets (MECHANICS), weapon switching (BGPROCESSING), and map assessment (MAP AWARENESS). It displays the score for each task and the combined score calculated from all three.

[0084] The details of the game score obtained from MPG are shown below. In the following analysis, only the large items indicated by ※ are used.

[0085] 1. Total Score (n) ※ 2. Mechanical ability (the ability to respond to perceptual stimuli to operate a mouse or keyboard) (n)※ Target hit count (n) Accuracy (%) Suitability (%) Ignored target (n) Total points lost (n) Center hit (n) Center hit (n) in a full hit scenario The number of points hit in the center (n) Mid-range hit (n) Mid-range hits (n) within a full hit. The number of points (n) from the central hit. Boundary hit (n) Boundary hits (n) in a full hit scenario Number of points hit on the boundary (n) Average click latency (s) Actions per minute (n) Lost center point (n) Target hit count (n) 3. Background processing capability (n) ※ Target hit count (n) Accuracy (%) Suitability (%) Ignored targets (n) 4. Map recognition (perception) ability (n)※ Fraction (n) Stagnation time (s) Points lost (n) Average time (s) per obstacle The study participants were nine healthy male university students (age: 20.10 ± 1.10 years, height: 178.71 ± 6.96 cm, weight: 60.9 ± 12.90 kg, mean ± standard deviation) who had not received drug treatment for any disease and did not exhibit symptoms of memory impairment. All participants had experience playing League of Legends (23.31 months ± 11.81 months), with an average weekly playtime of 3.33 ± 1.25 hours and a weekly play frequency of 3.33 ± 1.63 times. This study was approved by the ethics committee established by Little Software (No. 2023-0001, Feb 28, 2022). Participants were informed that they could withdraw from the study at any time, and the purpose, content, and methods of the study were explained, with written consent obtained. Participant ID9 was excluded from the data analysis due to ingestion of hay fever medication. Therefore, the valid data consisted of eight participants.

[0086] The experimental procedure is as follows.

[0087] (i) 0-5 minutes after the start of the test: MPG content description, pre-implementation, sensitivity setting (ii) 5–15 minutes after the start of the test: in a quiet state (iii) 15–18 minutes after the start of the test: Brainwave measurement at rest (iv) 18–22 minutes after the start of the test: POMS2 administration (before sample intake) (v) 22–23 minutes after the start of the trial: Sample (GABA or placebo) intake (vi) 23–55 minutes after the start of the experiment: implementation of the game task (32 minutes) and brainwave measurement (3 times in total: first half, middle stage, and final stage). (vii) 55–59 minutes after the start of the test: POMS2 administration (after sample ingestion) In (vi), multiple games were played with breaks interspersed throughout.

[0088] Test results The results of POMS2 show Figure 1 In experimental design A (multi-task), the CB (confusion-bewilderment) score at the end of the game task was significantly lower in the GABA intake group compared to the placebo group. This demonstrates for the first time that GABA (200 mg) intake can significantly improve POMS2 CB (confusion-bewilderment) scores under high-load conditions such as performing multiple tasks simultaneously.

[0089] The game score results are displayed Figure 2 In the experimental design A (multi-task), the total score in the GABA intake group was significantly higher than that in the placebo group.

[0090] (Example 2: Experimental Design B (Single Task)) The study evaluated whether GABA intake improved POMS2 scores under a single-task-based approach. The experimental design is shown below. For brainwave measurements, the analysis algorithm of the brainwave analysis application (Sports Sensibility, KANSEI) provided by Little Software was used.

[0091] <Design of Experiments B (Single Task)> • Participants: 10 (0 excluded, 10 for analysis) • Instrument used: Simple EEG meter • Sample: GABA (200mg) or placebo (dextrin) + 30ml water • Measurement items: brainwaves, simplified POMS2, AIM LAB (game-based) score • Double-blind crossover trial (washout period: 1 week) AIM LAB is a game that measures the basic skills of esports players. It is a game that only involves shooting at targets and displays four scores: total score, accuracy score (overall hit rate (%)), and kill score (number of kills).

[0092] The study participants were 10 healthy male university students who had not received drug treatment for any disease and did not exhibit symptoms of memory impairment (age: 21.00±3.55 years, height: 169.85±3.54 cm, weight: 71.0±19.89 kg, mean ± standard deviation). All participants had prior experience playing Valorant (23.4 months ± 12.71 months), with an average weekly playtime of 3.9 hours ± 1.76 hours and a weekly play frequency of 2.70 ± 0.98 times. This study was approved by the ethics committee established by Little Software (No. 2023-0001, Feb 28, 2022). Participants were informed that they could withdraw from the study at any time, and the purpose, content, and methods of the study were explained, with written consent obtained.

[0093] The experimental procedure is as follows.

[0094] (i) 0-5 minutes after the start of the test: AIM LAB content description, pre-implementation, sensitivity setting (ii) 5–15 minutes after the start of the test: in a quiet state (iii) 15–18 minutes after the start of the test: Brainwave measurement at rest (iv) 18–22 minutes after the start of the test: POMS2 administration (before sample intake) (v) 22–23 minutes after the start of the trial: Sample (GABA or placebo) intake (vi) 23–55 minutes after the start of the experiment: implementation of the game task (32 minutes) and brainwave measurement (3 times in total: first half, middle stage, and final stage). (vii) 55–59 minutes after the start of the test: POMS2 administration (after sample ingestion) In (vi), multiple games were played with breaks interspersed throughout.

[0095] Test results The results of POMS2 show Figure 3 In the experimental design B (single-task), no significant changes in scores were observed in either the GABA intake group or the placebo group.

[0096] The game score results are displayed Figure 4A and 4BIn the experimental design B (single-task), no significant changes in scores were observed in either the GABA intake group or the placebo group.

[0097] (Example 3: Effects of theanine, ornithine hydrochloride, and saffron extract on the CB fraction of POMS2) Using substances other than GABA known to have relaxing effects, and similar to Example 1, the improvement of POMS2 CB scores by ingesting these substances was evaluated under a multi-tasking condition. Theanine, ornithine hydrochloride, and saffron extract were used as test substances. Their respective relaxing effects are, for example, known below.

[0098] <Theanine> As a result of continuous 8-week intake of L-theanine (250 mg / day), depressive symptoms (HAMD-21 score) and anxiety (STAI score) were significantly improved (Hidese et al., 2019).

[0099] Ornithine hydrochloride In healthy adults, the scores for “confusion” and “anger-hostility” (POMS) were significantly reduced after consuming L-ornithine (400 mg) following alcohol consumption (Kokubo et al., 2013).

[0100] In a randomized, double-blind, placebo-controlled trial, healthy Japanese workers who ingested L-ornithine (400 mg / day) for eight consecutive weeks showed improvements in "anger." While no significant difference was observed in confusion, low values ​​were observed (Miyake et al., 2014).

[0101] <Saffron Extract> In clinical trials of saffron extract administered to adults, depression (POMS) was improved (Jackson et al., 2021).

[0102] The experimental design is shown below.

[0103] In addition to GABA intake, the subjects played the MPG game under the same conditions and procedures as in Example 1. After the pre-intake POMS2 administration, the subjects ingested either 250 mg of theanine (N=3), 400 mg of ornithine (N=3), or 30 mg of saffron extract (N=3). They then completed the game and underwent post-intake POMS2 administration.

[0104] The CB score results for POMS2 are shown in Figure 5 In the middle. All results show the average of 3 people. For example. Figure 5As shown, none of the theanine, ornithine hydrochloride, or saffron extracts improved the CB score of POMS2 after sample ingestion ("before" in the figure) compared to the pre-ingestion CB score ("after" in the figure). This suggests that even substances known to have relaxing effects cannot improve the confused-disoriented state in MPG games. Therefore, it suggests that the significant improvement in CB (confusion-disoriented) score induced by GABA shown in Example 1 is a different effect from simple stress reduction.

[0105] (Remark) As described above, although the preferred embodiments of this application have been illustrated, it should be understood that the scope of this application should be interpreted only according to the claims. It should be understood that the contents of patents, patent applications, and other documents cited in this specification should be referenced in the same manner as specifically described in this specification. This application claims priority to Japanese Patent Application No. 2024-41315 filed with the Japanese Patent Office on March 15, 2024, the contents of which are referenced in their entirety as constituting the content of this application.

[0106] Industrial availability According to the present invention, since GABA intake can improve or prevent the state of confusion and / or bewilderment in subjects, it is useful in fields related to stress management or mental health.

Claims

1. A composition for improving or preventing a state of confusion and / or bewilderment in an object, said composition containing γ-aminobutyric acid (GABA) as an active ingredient.

2. The composition according to claim 1, wherein, The state of confusion and / or bewilderment was assessed using the POMS2, or Mood State Scale, Version 2.

3. The composition according to claim 1, wherein, The composition inhibits and / or prevents the rise in the evaluation value of the confused and / or bewildered state.

4. The composition according to claim 1, wherein, The composition is used to improve or prevent states of confusion and / or bewilderment caused by cognitive load.

5. A composition for improving or preventing states of confusion and / or bewilderment caused by cognitive load on an object, said composition containing γ-aminobutyric acid, i.e., GABA, as an active ingredient, wherein the aforementioned states of confusion and / or bewilderment are evaluated using the POMS2 (Positive Mood State Scale, Version 2).

6. The composition according to claim 4 or 5, wherein, The cognitive load is caused by esports.

7. The composition according to claim 1, wherein, The content of GABA is approximately 10 mg to approximately 1000 mg.

8. The composition according to claim 7, wherein, The content of GABA is at least about 200 mg.

9. The composition according to claim 1, wherein, The composition is taken orally.

10. The composition according to claim 1, wherein, The composition is a beverage, food, supplement, food additive, quasi-pharmaceutical, or pharmaceutical.

11. The composition according to claim 1, wherein, The composition is in the form of a liquid, powder, tablet, or capsule.

12. The composition according to claim 1, wherein, The composition is used to improve scores in games and / or esports.

13. The composition according to claim 1, wherein, The composition is a food product, and the packaging of the food product is labeled with information indicating that it contains GABA as an active ingredient and improves or prevents confusion and / or disorientation.

14. The composition according to claim 1, wherein, The composition is used to improve or prevent mental sluggishness and / or decreased attention.

Citation Information

Patent Citations

  • Concentration power improving food

    JP2005013127A

  • Food and drink having relaxation effect

    JP2005348656A

  • Concentration power-improving drink or food

    JP2006061088A

  • Anti-stress composition

    JP2007031309A

  • Compositions containing L-theanine, proanthocyanidins and catechins and uses thereof

    JP2019520806A